Apr 15, 2008 Issue
The Diagnosis of Wheezing in Children [Article]

Wheezing in children is a common problem encountered by family physicians. Approximately 25 to 30 percent of infants will have at least one wheezing episode, and nearly one half of children have a history of wheezing by six years of age. The most common causes of wheezing in children include asthma,...

Jan 15, 2007 Issue
Levalbuterol Tartrate (Xopenex HFA) for the Treatment of Bronchospasm [STEPS]

Levalbuterol tartrate appears to be no more effective and offers no improvement in the side-effect profile compared with albuterol. The higher cost may make it appropriate for only a limited group of patients.

Jan 1, 2007 Issue
Leukotriene Inhibitors in the Treatment of Allergy and Asthma [Article]

Leukotriene inhibitors are the first new class of medications for the treatment of persistent asthma that have been approved by the U.S. Food and Drug Administration in more than two decades. They also have been approved for the treatment of allergic rhinitis. Prescriptions of leukotriene inhibitors...

Dec 1, 2006 Issue
Asthma and Other Wheezing Disorders in Children [Clinical Evidence Handbook]

What are the effects of treatments for acute asthma in children? What is the effect of single-agent prophylaxis in children taking inhaled beta agonists as needed for asthma?What are the effects of additional prophylactic treatments in patients with childhood asthma that is inadequately controlled b...

Jun 1, 2006 Issue
Long-Acting Beta2 Agonists as Steroid-Sparing Agents [Cochrane for Clinicians]

For adult patients who are taking a minimum maintenance dosage of inhaled corticosteroid for asthma, adding a long-acting beta2 agonist permits reduction of the dosage of inhaled corticosteroid by 253 mcg beclomethasone equivalent per day without worsening the patient's symptoms. In patients taking ...

May 15, 2005 Issue
Childhood Asthma: Treatment Update [Article]

The prevalence of childhood asthma has risen significantly over the past four decades. A family history of atopic disease is associated with an increased likelihood of developing asthma, and environmental triggers such as tobacco smoke significantly increase the severity of daily asthma symptoms and...

Jan 15, 2005 Issue
Omalizumab (Xolair) for Treatment of Asthma [STEPS]

Omalizumab is an immunomodulatory therapy for the control of symptoms in patients with moderate to severe allergic asthma uncontrolled with conventional therapy. Given its high cost, the requirement that it be administered in a physician’s office, and side effects, it is appropriate for use in only a small percentage of patients with asthma.

Jan 1, 2005 Issue
CDC Report on Asthma [Practice Guidelines]

Sep 15, 2004 Issue
Asthma Update: Part II. Medical Management [Article]

The National Asthma Education and Prevention Program recently updated its guidelines for the management of asthma. An evidence-based approach was used to examine several key issues regarding appropriate medical therapy for patients with asthma. The updated guidelines have clarified these issues and ...

Sep 1, 2004 Issue
Asthma Update: Part I. Diagnosis, Monitoring, and Prevention of Disease Progression [Article]

Despite increased scientific knowledge about asthma and improved therapeutic options, the disease continues to cause significant morbidity and mortality. The National Asthma Education and Prevention Program Expert Panel has updated its clinical guidelines on asthma medications, prevention of disease...

Pages: Previous 1 2 3 4 5 6 7 8 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now